Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released Tryvio from its REMS (Risk Evaluation and Mitigation Strategy) requirement (announced on…Original Article
FDA Approves an Updated Label for Tryvio (aprocitentan) Removing the REMS Requirement
